Nifty
Sensex
:
:
14581.45
48803.68
76.65 (0.53%)
259.62 (0.53%)

Pharmaceuticals & Drugs - Global

Rating :
35/99

BSE: 530549 | NSE: SHILPAMED

376.25
15-Apr-2021
  • Open
  • High
  • Low
  • Previous Close
  •  367.10
  •  381.40
  •  365.10
  •  367.10
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  179455
  •  673.15
  •  695.00
  •  311.60

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 3,069.08
  • 17.65
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 3,414.40
  • 0.29%
  • 2.09

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 53.25%
  • 6.13%
  • 16.80%
  • FII
  • DII
  • Others
  • 16.23%
  • 3.56%
  • 4.03%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.08
  • 4.85
  • 4.80

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.76
  • 6.04
  • 7.24

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.23
  • 7.34
  • 11.65

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 26.92
  • 28.33
  • 24.31

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.06
  • 3.84
  • 2.58

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.17
  • 20.97
  • 16.34

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Net Sales
191.25
236.85
-19.25%
278.94
289.92
-3.79%
222.87
160.99
38.44%
219.99
199.52
10.26%
Expenses
170.28
163.11
4.40%
210.25
221.91
-5.25%
157.11
132.19
18.85%
174.40
162.11
7.58%
EBITDA
20.97
73.74
-71.56%
68.68
68.00
1.00%
65.75
28.80
128.30%
45.60
37.40
21.93%
EBIDTM
10.96%
31.13%
24.62%
23.46%
29.50%
17.89%
20.73%
18.75%
Other Income
8.61
3.25
164.92%
9.20
5.82
58.08%
5.48
1.98
176.77%
8.91
3.09
188.35%
Interest
4.80
1.27
277.95%
3.95
0.82
381.71%
4.00
1.46
173.97%
1.01
1.41
-28.37%
Depreciation
13.72
10.97
25.07%
12.70
10.66
19.14%
12.33
10.66
15.67%
11.55
10.54
9.58%
PBT
11.05
64.76
-82.94%
61.23
62.34
-1.78%
115.74
18.66
520.26%
41.57
28.09
47.99%
Tax
2.92
10.53
-72.27%
15.99
11.18
43.02%
29.14
4.05
619.51%
7.55
5.61
34.58%
PAT
8.14
54.24
-84.99%
45.24
51.16
-11.57%
86.60
14.61
492.74%
34.02
22.49
51.27%
PATM
4.25%
22.90%
16.22%
17.65%
38.86%
9.07%
15.47%
11.27%
EPS
0.94
6.75
-86.07%
5.57
6.23
-10.59%
10.59
1.93
448.70%
4.24
2.93
44.71%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
913.05
907.91
733.39
788.83
779.16
716.43
613.80
571.38
371.32
318.18
290.29
Net Sales Growth
2.90%
23.80%
-7.03%
1.24%
8.76%
16.72%
7.42%
53.88%
16.70%
9.61%
 
Cost Of Goods Sold
300.94
277.73
257.03
355.87
371.81
366.19
323.16
313.26
213.95
183.22
162.98
Gross Profit
612.11
630.18
476.36
432.95
407.36
350.25
290.63
258.12
157.38
134.96
127.31
GP Margin
67.04%
69.41%
64.95%
54.89%
52.28%
48.89%
47.35%
45.17%
42.38%
42.42%
43.86%
Total Expenditure
712.04
693.39
579.39
637.60
617.55
556.44
487.38
455.40
301.63
257.08
219.70
Power & Fuel Cost
-
38.76
33.57
28.86
26.30
21.90
19.29
17.37
10.67
9.38
7.03
% Of Sales
-
4.27%
4.58%
3.66%
3.38%
3.06%
3.14%
3.04%
2.87%
2.95%
2.42%
Employee Cost
-
196.59
176.40
149.35
127.87
90.09
82.30
67.83
42.56
33.68
28.37
% Of Sales
-
21.65%
24.05%
18.93%
16.41%
12.57%
13.41%
11.87%
11.46%
10.59%
9.77%
Manufacturing Exp.
-
79.19
61.23
59.96
52.55
45.35
36.55
27.44
16.92
12.89
8.35
% Of Sales
-
8.72%
8.35%
7.60%
6.74%
6.33%
5.95%
4.80%
4.56%
4.05%
2.88%
General & Admin Exp.
-
70.26
27.20
22.50
16.95
14.11
10.64
9.53
9.51
7.87
5.64
% Of Sales
-
7.74%
3.71%
2.85%
2.18%
1.97%
1.73%
1.67%
2.56%
2.47%
1.94%
Selling & Distn. Exp.
-
10.40
6.72
6.37
4.75
7.27
5.99
7.29
4.43
3.19
4.63
% Of Sales
-
1.15%
0.92%
0.81%
0.61%
1.01%
0.98%
1.28%
1.19%
1.00%
1.59%
Miscellaneous Exp.
-
20.47
17.23
14.68
17.32
11.54
9.45
12.68
3.59
6.86
4.63
% Of Sales
-
2.25%
2.35%
1.86%
2.22%
1.61%
1.54%
2.22%
0.97%
2.16%
0.93%
EBITDA
201.00
214.52
154.00
151.23
161.61
159.99
126.42
115.98
69.69
61.10
70.59
EBITDA Margin
22.01%
23.63%
21.00%
19.17%
20.74%
22.33%
20.60%
20.30%
18.77%
19.20%
24.32%
Other Income
32.20
22.22
15.56
32.62
29.34
11.36
6.93
9.12
5.01
8.28
8.95
Interest
13.76
4.56
3.68
2.66
3.13
3.93
4.05
3.52
2.27
2.31
2.63
Depreciation
50.30
43.78
42.06
37.22
30.64
23.14
21.41
23.22
15.34
14.36
12.96
PBT
229.59
188.40
123.82
143.96
157.17
144.28
107.89
98.35
57.10
52.71
63.95
Tax
55.60
33.49
26.18
33.91
42.04
35.62
35.22
20.30
9.53
12.22
14.60
Tax Rate
24.22%
17.78%
18.22%
23.56%
27.54%
25.11%
32.66%
21.27%
16.72%
22.91%
22.83%
PAT
174.00
156.50
120.28
112.43
113.71
109.84
73.69
75.67
47.35
41.23
49.35
PAT before Minority Interest
175.05
154.91
117.52
110.05
110.59
106.24
72.62
75.15
47.47
41.11
49.35
Minority Interest
1.05
1.59
2.76
2.38
3.12
3.60
1.07
0.52
-0.12
0.12
0.00
PAT Margin
19.06%
17.24%
16.40%
14.25%
14.59%
15.33%
12.01%
13.24%
12.75%
12.96%
17.00%
PAT Growth
22.11%
30.11%
6.98%
-1.13%
3.52%
49.06%
-2.62%
59.81%
14.84%
-16.45%
 
EPS
21.35
19.20
14.76
13.80
13.95
13.48
9.04
9.28
5.81
5.06
6.06

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
1,329.36
1,197.58
1,085.03
986.90
639.26
546.94
396.45
320.42
275.98
224.68
Share Capital
8.15
8.15
8.15
8.01
7.71
7.71
7.36
4.90
4.90
4.80
Total Reserves
1,321.21
1,189.43
1,076.88
978.88
631.55
539.23
389.09
315.52
271.07
213.85
Non-Current Liabilities
256.94
166.62
153.48
251.26
67.23
154.15
104.53
98.51
31.13
31.85
Secured Loans
164.48
80.39
67.09
141.20
0.03
71.03
37.43
70.47
5.07
11.42
Unsecured Loans
0.53
0.70
1.03
1.30
0.00
31.30
30.05
0.00
0.00
0.00
Long Term Provisions
26.17
21.77
20.32
16.89
13.96
11.75
9.93
6.92
6.34
5.71
Current Liabilities
407.74
253.44
265.84
236.90
222.07
189.06
166.84
123.77
121.14
80.21
Trade Payables
89.46
80.72
103.74
111.86
106.48
75.50
92.98
51.26
56.72
27.90
Other Current Liabilities
142.11
81.62
59.59
28.03
36.49
49.32
38.23
23.38
20.34
16.65
Short Term Borrowings
165.27
86.58
98.12
92.41
74.10
58.47
30.27
45.07
41.24
33.15
Short Term Provisions
10.90
4.52
4.39
4.60
5.00
5.77
5.37
4.06
2.83
2.51
Total Liabilities
1,986.13
1,610.02
1,499.13
1,472.22
930.89
904.54
677.83
551.42
433.11
338.21
Net Block
650.44
558.01
534.20
491.93
393.41
316.06
294.42
180.67
166.61
146.25
Gross Block
986.42
853.16
793.24
704.89
582.20
476.34
448.38
300.89
271.30
232.84
Accumulated Depreciation
335.98
295.15
259.04
212.96
188.79
160.28
153.96
120.22
104.70
86.59
Non Current Assets
1,365.35
1,064.96
827.16
742.33
576.68
576.77
443.89
339.18
244.95
159.79
Capital Work in Progress
666.25
429.12
209.85
140.51
91.90
221.62
111.03
129.15
57.71
2.72
Non Current Investment
10.45
2.25
20.79
27.99
34.15
0.19
0.21
0.14
0.11
3.65
Long Term Loans & Adv.
32.42
48.75
37.47
77.09
51.86
38.74
38.18
28.82
20.17
6.62
Other Non Current Assets
5.78
26.84
24.86
4.80
5.36
0.16
0.06
0.40
0.34
0.00
Current Assets
620.78
545.06
671.97
729.88
354.21
327.61
233.74
211.99
187.87
178.39
Current Investments
0.00
0.00
119.54
224.62
59.63
65.35
10.14
50.28
68.02
0.00
Inventories
226.43
187.67
188.71
190.00
134.23
130.78
123.25
74.33
67.32
43.33
Sundry Debtors
243.72
203.73
220.27
170.93
125.43
81.37
67.96
41.79
40.53
40.13
Cash & Bank
44.56
94.54
73.83
100.39
11.03
18.42
9.19
16.87
2.27
87.20
Other Current Assets
106.06
45.04
26.08
22.00
23.90
31.69
23.20
28.72
9.72
7.72
Short Term Loans & Adv.
29.25
14.08
43.54
21.95
8.90
4.91
3.23
2.86
3.01
1.56
Net Current Assets
213.04
291.62
406.13
492.98
132.14
138.55
66.90
88.22
66.73
98.18
Total Assets
1,986.13
1,610.02
1,499.13
1,472.21
930.89
904.54
677.83
551.42
433.10
338.21

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
123.72
146.78
44.92
37.48
128.70
68.81
70.04
43.64
56.73
40.86
PBT
188.40
143.70
136.77
146.49
140.36
107.84
95.45
57.00
53.51
64.13
Adjustment
41.32
20.44
18.83
17.19
20.61
26.46
19.62
11.52
10.19
10.42
Changes in Working Capital
-63.80
18.71
-69.66
-92.61
-2.70
-40.11
-23.44
-13.90
0.77
-21.04
Cash after chg. in Working capital
165.92
182.85
85.94
71.08
158.27
94.19
91.62
54.62
64.46
53.51
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-42.20
-36.07
-41.02
-33.60
-29.56
-25.38
-21.58
-10.98
-7.73
-12.61
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-288.85
-196.16
-8.76
-262.23
-109.20
-195.18
-48.93
-95.21
-152.31
7.77
Net Fixed Assets
-4.28
-256.96
-136.75
-172.23
-92.14
-78.46
-61.02
-83.52
-79.20
-5.23
Net Investments
-4.44
141.85
95.51
-172.72
-14.09
-64.38
12.08
13.84
-73.05
-24.39
Others
-280.13
-81.05
32.48
82.72
-2.97
-52.34
0.01
-25.53
-0.06
37.39
Cash from Financing Activity
175.50
10.06
-60.91
312.70
-19.65
135.05
-28.34
66.31
10.02
35.93
Net Cash Inflow / Outflow
10.38
-39.32
-24.75
87.95
-0.15
8.68
-7.23
14.74
-85.56
84.56
Opening Cash & Equivalents
34.36
73.83
99.97
7.05
3.61
9.19
16.87
2.27
87.83
2.65
Closing Cash & Equivalent
44.56
34.36
73.83
99.97
6.43
18.42
9.19
16.87
2.27
87.20

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
163.06
146.89
133.09
123.17
82.91
70.92
107.72
43.52
74.94
60.67
ROA
8.62%
7.56%
7.41%
9.20%
11.58%
9.18%
12.23%
9.64%
10.66%
16.84%
ROE
12.26%
10.30%
10.62%
13.60%
17.92%
15.40%
20.98%
15.93%
16.63%
30.96%
ROCE
12.41%
11.05%
11.71%
15.91%
19.90%
17.90%
20.48%
15.04%
18.02%
28.98%
Fixed Asset Turnover
0.99
0.89
1.06
1.22
1.36
1.34
1.54
1.32
1.28
1.30
Receivable days
89.94
105.51
90.20
69.00
52.26
43.99
34.62
39.70
45.47
46.24
Inventory Days
83.24
93.66
87.32
75.49
66.97
74.84
62.33
68.31
62.38
57.79
Payable days
46.83
58.00
61.51
60.89
60.10
62.86
57.06
63.94
59.10
55.44
Cash Conversion Cycle
126.35
141.17
116.00
83.61
59.13
55.97
39.90
44.07
48.76
48.59
Total Debt/Equity
0.29
0.16
0.18
0.24
0.14
0.34
0.30
0.41
0.22
0.26
Interest Cover
42.34
40.09
55.10
49.69
37.07
27.63
28.09
26.13
24.13
25.28

News Update:


  • Shilpa Medicare gets tentative USFDA’s nod for Apremilast tablets
    5th Mar 2021, 13:40 PM

    The newly approved product is a generic equivalent of reference listed drug (RLD) Otezla of Celgene

    Read More
  • Shilpa Medicare launches first women intimate cleansing spray ‘SwatchShil’
    4th Mar 2021, 11:56 AM

    ‘SwatchShil’ will give Shilpa an entry with differentiated products into rapidly growing Women intimate hygiene products segment

    Read More
  • Shilpa Medicare receives import alert
    18th Feb 2021, 12:51 PM

    Three products have been exempted from the Import Alert - Azacitidine for Injection, Cyclophosphamide Capsules and Erlotinib Tablets

    Read More
  • Shilpa Medicare launches Sunitinib Capsules
    15th Feb 2021, 12:17 PM

    Three strengths of Sunitinib capsules 12. 5 mg, 25 mg and 50 mg is launched at an attractive price for the benefit of patients

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.